Plasmodium Immunotherapy is under clinical development by CAS-Lamvac Biotech and currently in Phase II for Colorectal Cancer.

The immune system plays a pivotal role in colorectal cancer (CRC), with immune cells such as T cells, natural killer (NK) cells, macrophages, and dendritic ...

The battle against rectal cancer has entered an extraordinary new phase with the advent of immunotherapy, offering hope to ...

Jimmy Carter’s 2015 melanoma diagnosis introduced the world to immunotherapy, sparking future cancer research. Millions of ...

Bristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients with advanced colorectal cancer. The FDA approved the combination ...

Dec. 23, 2024 — A research team has developed a groundbreaking technology that can treat colon cancer by converting cancer cells into a state resembling normal colon cells without killing them ...